Vancouver, British Columbia--(Newsfile Corp. - January 3, 2018) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:
18H) (the "Company" or "PreveCeutical") announces that it has amended the terms of its previously announced non-brokered
private placement (the "Financing") of $0.75 units (see news release dated November 22, 2017).
Under the amended terms of the Financing, the Company will offer up to 6.6 million units (each, a "Unit") at the price of
$0.50 per Unit. Each Unit will consist of one common share of the Company (each, a "Share") and one-half of one warrant (each, a
"Warrant"), with each whole Warrant entitling the holder thereof to purchase one common share of the Company at an exercise price
of $0.75 per Share for a period of 12 months from the closing of the Financing (the "Closing"). The Units will be subject to
an acceleration provision whereby if the closing price of the Shares on the Canadian Securities Exchange (the "CSE") is $1.00
for a minimum of ten consecutive trading days, the Warrants will expire at 4.00 p.m. (Vancouver time) on the 30th day after the
date on which the Company provides notice of such accelerated expiry to the holders of the Warrants. The Closing is expected to
occur on or about February 15, 2018. The Shares and the Warrants comprising the Units will be subject to a hold period of four
months and one day in Canada.
The proceeds of the Financing are intended to be used to fund the Company's research & development programs and for general
working capital purposes. The Company may pay finder's fees on a portion of the Financing equal to 10% of the gross proceeds
raised, payable in cash and/or securities, as the Company in its sole discretion may determine and in accordance with the policies
of the CSE. The Financing is subject to CSE and other applicable stock exchange and regulatory approval.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in
the United States, or in any jurisdiction in which such an offer or sale would be unlawful. The securities described herein have
not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any
United States state securities laws, and may not be offered or sold in the United States or to the account or benefit of a "U.S.
person" (as defined in Regulation S under the 1933 Act) or a person in the United States absent registration or an applicable
exemption from the registration requirements.
About PreveCeutical
PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and
nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs,
including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain
delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive
analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic
product for treating athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and
potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom.
For more information about PreveCeutical, please visit www.PreveCeutical.com, follow
us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
On Behalf of the Board of Directors
"Stephen Van Deventer"
Chairman & CEO
For further information, please contact:
Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking
statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private
Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are
forward-looking statements and include any statements regarding beliefs, plans and expectations regarding the future, including,
the Closing and the amount of the Financing, the use of proceeds from the Financing, and anticipated business plans and timing of
future business activities of the Company. Often, but not always, forward-looking statements can be identified by words such as
"pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates",
"believes", "potential" or variations of such words including negative variations thereof and phrases that refer to certain
actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from
those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to investor
interest in the Financing and the ability of the Company to, among other things, obtain any required governmental, regulatory or
stock exchange approvals, permits, consents or authorizations required, including CSE acceptance of the Financing and any planned
future activities, complete its research programs as planned, and obtain the financing required to carry out its planned future
activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies
affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company.
Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are
reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate.
Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the
Company from time-to-time. These reports and the Company's Canadian continuous disclosure filings are available at www.sedar.com.
Readers are cautioned not to put undue reliance on forward-looking statements. These forward-looking statements are made as of
the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the
forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking
statements.
**NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO UNITED STATES NEWS WIRE
SERVICES**
